PVG Asset Management Corp Acquires New Stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

PVG Asset Management Corp bought a new position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 11,786 shares of the biopharmaceutical company’s stock, valued at approximately $183,000.

A number of other large investors have also made changes to their positions in CPRX. Arizona State Retirement System raised its stake in shares of Catalyst Pharmaceuticals by 2.2% in the second quarter. Arizona State Retirement System now owns 29,733 shares of the biopharmaceutical company’s stock worth $461,000 after buying an additional 654 shares during the period. Ameritas Investment Partners Inc. boosted its position in shares of Catalyst Pharmaceuticals by 6.9% in the first quarter. Ameritas Investment Partners Inc. now owns 11,116 shares of the biopharmaceutical company’s stock worth $177,000 after purchasing an additional 720 shares during the period. XTX Topco Ltd increased its stake in shares of Catalyst Pharmaceuticals by 7.5% in the second quarter. XTX Topco Ltd now owns 11,134 shares of the biopharmaceutical company’s stock worth $172,000 after purchasing an additional 773 shares in the last quarter. GAMMA Investing LLC raised its position in shares of Catalyst Pharmaceuticals by 72.9% during the 1st quarter. GAMMA Investing LLC now owns 1,942 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 819 shares during the period. Finally, Strategic Advocates LLC boosted its holdings in Catalyst Pharmaceuticals by 6.5% in the 2nd quarter. Strategic Advocates LLC now owns 14,142 shares of the biopharmaceutical company’s stock worth $219,000 after buying an additional 864 shares during the period. 79.22% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on CPRX. Truist Financial lifted their target price on Catalyst Pharmaceuticals from $25.00 to $30.00 and gave the company a “buy” rating in a research note on Friday, August 9th. Oppenheimer restated an “outperform” rating and set a $29.00 target price on shares of Catalyst Pharmaceuticals in a research report on Thursday, June 6th. StockNews.com upgraded shares of Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Friday, August 9th. HC Wainwright increased their price objective on shares of Catalyst Pharmaceuticals from $26.00 to $30.00 and gave the company a “buy” rating in a report on Monday, August 12th. Finally, Citigroup boosted their price target on shares of Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the stock a “buy” rating in a research report on Friday, August 9th. Six research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Catalyst Pharmaceuticals has an average rating of “Buy” and a consensus price target of $29.50.

Insider Transactions at Catalyst Pharmaceuticals

In related news, insider Carmen Jeffrey Del sold 36,058 shares of the company’s stock in a transaction on Friday, August 9th. The stock was sold at an average price of $18.42, for a total transaction of $664,188.36. Following the completion of the sale, the insider now directly owns 12,369 shares in the company, valued at approximately $227,836.98. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In related news, Director David S. Tierney sold 15,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 21st. The stock was sold at an average price of $20.10, for a total value of $301,500.00. Following the sale, the director now owns 348,874 shares in the company, valued at $7,012,367.40. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Carmen Jeffrey Del sold 36,058 shares of the firm’s stock in a transaction on Friday, August 9th. The stock was sold at an average price of $18.42, for a total transaction of $664,188.36. Following the transaction, the insider now directly owns 12,369 shares of the company’s stock, valued at approximately $227,836.98. The disclosure for this sale can be found here. In the last quarter, insiders sold 201,058 shares of company stock valued at $4,018,188. Company insiders own 11.00% of the company’s stock.

Catalyst Pharmaceuticals Stock Performance

Shares of CPRX stock opened at $19.88 on Tuesday. Catalyst Pharmaceuticals, Inc. has a 52-week low of $11.55 and a 52-week high of $21.67. The firm has a market capitalization of $2.35 billion, a P/E ratio of 36.81, a P/E/G ratio of 3.27 and a beta of 0.75. The stock has a 50 day moving average price of $19.28 and a 200 day moving average price of $16.98.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last announced its quarterly earnings data on Wednesday, August 7th. The biopharmaceutical company reported $0.52 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.39 by $0.13. The company had revenue of $122.71 million for the quarter, compared to analysts’ expectations of $111.76 million. Catalyst Pharmaceuticals had a return on equity of 27.77% and a net margin of 15.69%. As a group, sell-side analysts forecast that Catalyst Pharmaceuticals, Inc. will post 1.82 EPS for the current year.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.